Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Muhammad Waqas

Advanced Heart Failure and Transplant Cardiology Little Rock, AR Medical Doctor

NPI 1609060334 CMS profile 72178

10100 Kanis Rd, Little Rock, AR 72205

Open in the dashboard

General payments

$102,410

801 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$57,497 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Muhammad Waqas of Little Rock, AR is reported in the CMS Open Payments database as having received $102,410 across 801 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $57,497 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,643 90
2024 General $1,797 100
2023 General $1,713 88
2022 General $21,433 101
2021 General $11,312 136
2020 General $16,998 117
2019 General $47,513 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Muhammad Waqas
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Muhammad Waqas were reported at $1,643. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Muhammad Waqas Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $47,513 $863 $224–$4,562 $163
2020 $16,998 $452 $122–$3,992 $114
2021 $11,312 $550 $159–$3,571 $132
2022 $21,433 $729 $221–$4,357 $149
2023 $1,713 $1,002 $309–$5,827 $160
2024 $1,797 $931 $273–$5,204 $164
2025 $1,643 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. United Therapeutics Corporation $43,837 104 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $21,002 55 payments
  3. Abiomed $11,690 102 payments
  4. Novartis Pharmaceuticals Corporation $10,508 134 payments
  5. Actelion Pharmaceuticals US, Inc. $9,707 200 payments
  6. Abbott Laboratories $2,045 45 payments
  7. AstraZeneca Pharmaceuticals LP $1,225 50 payments
  8. Merck Sharp & Dohme Corporation $405 25 payments
  9. Pfizer Inc. $392 18 payments
  10. Medtronic Vascular, Inc. $254 3 payments
  11. Other $1,345 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,801 31 payments
  2. Food and Beverage $16,252 729 payments
  3. Consulting Fee $13,503 4 payments
  4. Travel and Lodging $10,562 30 payments
  5. Honoraria $6,000 1 payment
  6. Education $291 6 payments
Products named General payments · program years 2019–2025
  1. ORENITRAM $21,337 56 payments
  2. Adempas $20,888 47 payments
  3. TYVASO $16,464 28 payments
  4. REMODULIN $13,327 24 payments
  5. Impella $11,405 90 payments
  6. ENTRESTO $9,688 70 payments
  7. OPSUMIT Cardiovascular Disorders $5,842 7 payments
  8. UPTRAVI $3,476 168 payments
  9. NONE $3,466 8 payments
  10. OPSUMIT Cardiology $3,420 163 payments
  11. Other $7,300 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

7,090

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$21,845,557

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

40.5%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opsumit Macitentan Brand 691 $8,726,838
Uptravi Selexipag Brand 144 $3,160,285
Adempas Riociguat Brand 198 $2,708,591
Vyndamax Tafamidis Brand 109 $2,657,231
Tyvaso Dpi Treprostinil Brand 83 $1,908,813
Orenitram Er Treprostinil Diolamine Brand 107 $680,929
Farxiga Dapagliflozin Propanediol Brand 686 $483,007
Entresto Sacubitril/Valsartan Brand 442 $384,679
Ambrisentan Generic 110 $320,417
Winrevair Sotatercept-Csrk Brand 17 $233,838

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$207,058

Medicare's payments for the services billed

Medicare patients

433

Average age 74

Services billed

2,605

204 women, 229 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 68%
Atrial fibrillation 62%
Chronic kidney disease 49%
Arthritis 48%
Diabetes 46%
COPD 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TYVASO
  • United Therapeutics Corporation $248
$248 83 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $217
  • Johnson & Johnson Health Care Systems Inc. $9
$226 691 —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $181
  • Johnson & Johnson Health Care Systems Inc. $9
$191 144 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $168
$168 17 —
Adempas
  • Bayer HealthCare Pharmaceuticals Inc. $136
$136 198 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

801 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record